Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

Digital PET detects smaller cancerous lesions, produces images nuclear medicine experts prefer

Providers believe the digital modality could ultimately provide a more accurate cancer diagnosis compared to conventional PET, authors reported in the Journal of Nuclear Medicine.

Thumbnail

NorthStar’s new FDA approval means ‘immediate increase’ in Mo-99 production

The U.S Food and Drug Administration gave the go-ahead for two additional molybdenum-99 filling lines at the company's Columbia, Missouri, facility.

Thumbnail

FDA approves International Isotopes’ I-131 therapeutic agent

Idaho-based International Isotopes has received U.S. Food and Drug Administration approval for its radioactive therapeutic agent used to treat thyroid cancers.

Thumbnail

Highly touted Alzheimer’s drugs fail to slow cognitive decline

Randall Batemen, MD, principal investigator of the research and a neurologist at Washington University in St. Louis, told the New York Times the results were "really crushing."

NIH division awards $2.5M for PET-based Alzheimer's research

The National Institute on Aging awarded Wake Forest School of Medicine a five-year grant to examine if a novel PET tracer can help researchers tackle the disease.

Thumbnail

Brain PET research at critical ‘crossroads,' must move toward collaboration to advance

Nuclear medicine experts called on the field to work together and share data in order to produce the sample sizes needed for further breakthroughs.

Thumbnail

FDA approves PET tracer trial testing ability to diagnose multiple sclerosis

The imaging agent—Myeliviz—will be tested in humans for the first time, and may change the way clinicians diagnose the autoimmune disease.

Thumbnail

PET/MRI spots breast cancer biomarkers for risk-based screening methods

Imaging markers such as breast parenchymal uptake varied greatly between women with benign and malignant lesions, according to a study published in the Journal of Nuclear Medicine.